** Drug developer Cellectar Biosciences' CLRB.O shares fall 44.3% to 71 cents premarket
** On Tuesday, CLRB said it may sell its experimental cancer drug to a larger firm or partner with it
** The decision follows discussions with the U.S. FDA on approval requirements for the drug - CLRB
** Co says it will lay off 60% of its employees to extend its operational runway into Q3 2025
** As of Dec. 31, 2023, CLRB had 20 employees - SEC filing
** As of last close, stock has fallen 53.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。